• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Lannett CDMO

    Syngene International Ltd.

    Societal CDMO

    Bachem

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Lannett CDMO

    Syngene International Ltd.

    Societal CDMO

    Bachem

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Clinical Trial Feasibility

    How to reduce late-stage trial risk with feasibility analysis

    Clinical Trial Feasibility
    Alan Scott and Denis McMillan, PAREXEL International04.05.19
    Late-stage clinical research remains a risky and costly business despite the reasonable expectation that risks would decrease as products advance successfully through the earlier phases of development. But, in fact, about half of Phase III trials fail.

    Trials fail for a variety of reasons, including flawed science or study design, suboptimal dosing, poor study execution, slow patient enrollment, high dropout rates and, finally, a failure to demonstrate clinical or commercial value. 

    Most companies conduct at least some form of feasibility testing on their trial designs because they know that changes and miscalculations can cause delays and cost money. For example, the direct cost to implement a single protocol amendment averages approximately $500,000 in unplanned expenses and adds 61 days to project timelines. But a rudimentary glance at feasibility is not enough.

    The surest way to mitigate and even avoid many of the risks of later-stage studies is to methodically and comprehensively examine the feasibility of a study’s design before it starts.

    Once you’ve determined what’s feasible, who’s listening? 

    Feasibility analysis exists to inform clinical decision-makers about a variety of risks. But identifying and quantifying them is not enough. Risk analysis should stimulate action. And to drive action, feasibility analysis should be informed by quality data from multiple sources. There are many reasons why clinical trials fail to meet timelines, and feasibility-testing must look at all aspects of operationalizing a trial (see Table 1).


    Table 1. Key Elements of a Systematic Risk-Based Feasibility Analysis

    Accessing and interpreting the vast number of potential data sources that can aid in vetting a trial’s design is not always straightforward. Assessing the credibility of each data source is crucial and requires deep expertise. The increasing complexity of modern trial designs—which include, for example, narrow genetic eligibility criteria that require screening and involve administering technologically-advanced, expensive treatments—requires increasingly sophisticated analytic methods to determine possible impacts on a trial’s success. Adding to this difficulty, feasibility analyses are almost always conducted under tight time constraints.

    The ability to quantify and communicate risk empowers sponsors to mitigate it. Every solution discovered through feasibility analyses will be a compromise between market access, time, cost and science. Feasibility data should both motivate and reassure decision-makers. Suggesting that a study design “might be challenging” is one thing; putting a monetary value on what the challenges may cost a sponsor is a surer way to get the attention of senior management.

    The primacy of human data
    There is no one approach to feasibility analysis that will fit all trials. And the best data to gauge feasibility, as well as the best analytic tools to obtain that data, depend on the risks of the specific protocol, especially as they concern patients.

    For example, recently a major regulatory agency requested that a firm developing a drug for a serious neurologic condition conduct a placebo-controlled trial to demonstrate efficacy. The agency-mandated study design assumed, among other things, that patients had no therapeutic alternatives because none had gained formal regulatory approval. In fact, families had multiple off-label therapeutic options—some drugs approved for other conditions had shown efficacy and were being offered to patients on a routine basis—meaning that a placebo-controlled trial would have difficulty recruiting and retaining patients. It possibly also would be unethical. The firm engaged Parexel to conduct an arm’s-length analysis of the protocol’s viability. We interviewed patients and physicians, key opinion leaders, regulatory experts and bioethicists from a wide range of institutions about the trial’s design and how the treatment landscape had changed in recent years. We were able to quantify the negative impact of such a design on enrollment and retention and offer a data-driven argument that illustrated why a placebo-controlled trial was not feasible.

    How the patient population is defined also has a direct impact on how well a study can be executed in a real world setting. For instance, if the entry criteria are too tight, patients may be too hard to find. Sponsors must therefore strike a balance between enrolling: 1) a strictly controlled, homogeneous population to reduce the level of noise in the data and increase the probability of an efficacy finding; and 2) enough patients fast enough to hew to development timelines, which could necessitate broadening entry criteria.

    How many patients will make it through pre-screening, informed consent, screening and all the way to randomization? If, for every 100 patients screened, the sponsor ends up with one randomized patient, that will determine how many patients need to enter the top of the trial’s patient funnel.

    And what is the burden of patient recruitment on site resources and is this adequately compensated for in the research funding that sites receive? How do we motivate the principal investigator to pay for additional resources?

    Deeper understanding and quantification of the target patient population can reduce uncertainty. For example, a symptom monitoring assessment provides a picture of the prevalence of particular symptoms in a population—symptoms that may be crucial for patient trial eligibility. Electronic health data or prescription fulfillment records may be used to acquire a snapshot of a sample of patient’s current treatments and disease history which could play a critical part in the trial design and speed recruitment.

    Practical designs are grounded in what motivates patients and physicians
    A recruitment funnel analysis is both art and science: estimates need to be made in light of how patients, their families and physicians make their decision on whether to participate in a trial, or not.

    Several tools can be used to understand how those choices are made. At Parexel, we rely on medical, therapeutic area and operational experts within our own organization, and we seek advice from external experts, opinion leaders, and experienced principal investigators and their staff within our global alliance network of 350 sites.

    Engaging with investigators, patients and study site nurses who represent a critical, and often untapped reservoir of practical information and expertise provides invaluable insight. Sponsors can and should modify their protocols to address findings from surveys of these communities. In some cases, the design of a protocol may remain unchanged, but the geographic footprint of the trial can be improved. 

    For example, a recent Alzheimer’s disease study required a lumbar puncture (LP) procedure to obtain a cerebral spinal fluid sample (CSF). When a trial requires an invasive procedure of this kind it’s important to have deep knowledge of standards of care and cultural idiosyncrasies. Different countries have different levels of acceptance for certain interventions. In some European countries, LPs are widely accepted and routine; in other countries, they are rare and unfamiliar. If a study includes a non-negotiable burden—in this case, CSF sampling was needed to measure a biomarker hypothesized to be an indicator of disease progression—by understanding cultural standards, sponsors can choose sites in geographies that convey the best chance of recruitment success.

    To gain an appreciation of the patient (and family/caregiver) perspective, Parexel routinely conducts a patient burden analysis of study designs, which involves asking questions such as:
    • What are the demographics of the patients in the study and will it impact their habits? Are they elderly and therefore may have difficulty leaving home? Young adults who can travel easily? Or, small children who must be supervised by parents?
    • What is life like with this disease? Do patients have frequent medical appointments and/or hospitalizations, similar to trial site visits and assessments, or very few medical interventions, making trial-related testing and procedures more out of the ordinary?
    • What will it mean to undergo this procedure/intervention/assessment visit every week for 12 weeks when the patient and his or her family may be struggling with a frightening or discouraging disease diagnosis?
    • How far away from sites do most patients live, and what kind of transportation obstacles might they confront?
    Recently, a sponsor asked Parexel to analyze a pediatric trial that required three consecutive days of in-clinic monitoring as part of the protocol. Worried about that burden, we surveyed the families of patients with the condition for insight into how they viewed the protocol. We were surprised to find families did not find three days of on-site monitoring a burden as the untreated side effects of the condition regularly landed them in hospital settings with their children for prolonged periods. Rather, their biggest worry was about childcare options for their other, non-affected children. This insight allowed the trial’s sponsor to provide solutions that targeted the actual rather than the assumed problem; in this case, to help families arrange childcare.

    Knowing what you don’t know is valuable in managing risk
    Done correctly, analytical pressure-testing of a trial’s protocol enables sponsors to identify and eliminate unrealistic or impractical elements of the design, thereby reducing the risk of waste, missing development deadlines or outright failure. Even identifying uncertainties is worthwhile before a trial starts, giving sponsors insight as to where problems may arise and time to develop mitigation strategies.

    Ultimately, feasibility testing should drive clinical decision-makers to put contingency plans in place that would not exist otherwise. And that will increase a late-stage trial’s chance of success. 
    Related Searches
    • late-stage
    • patients
    • study
    • Phase III
    Suggested For You
    Clinical Trials are Transforming Right Before Our Eyes Clinical Trials are Transforming Right Before Our Eyes
    Clinical Ink Adds Executives Clinical Ink Adds Executives
    Parexel Appoints Chief Patient Officer Parexel Appoints Chief Patient Officer
    Data Management in the Face of Growing Trial Complexity Data Management in the Face of Growing Trial Complexity
    AlzProtect & PAREXEL Biotech Enter Collaboration AlzProtect & PAREXEL Biotech Enter Collaboration
    Immuno-oncology Safety Assessment Immuno-oncology Safety Assessment
    Selexis, Turgut Expand Biosimilar Development Pact Selexis, Turgut Expand Biosimilar Development Pact
    PAREXEL Adds Oncology Expertise  PAREXEL Adds Oncology Expertise
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL
    Leveraging AI to Advance Discovery, Development and Delivery Leveraging AI to Advance Discovery, Development and Delivery
    Taiho and Cullinan Enter Cancer Collaboration Taiho and Cullinan Enter Cancer Collaboration
    Cytel Appoints CEO Cytel Appoints CEO
    Managing Outsourced Clinical Trials Managing Outsourced Clinical Trials
    PAREXEL Launches Biotech Division PAREXEL Launches Biotech Division
    Chi-Med and Lilly Amend 2013 Agreement Chi-Med and Lilly Amend 2013 Agreement

    Related Online Exclusives

    • Clinical Trials | Information Technology
      Clinical Trials are Transforming Right Before Our Eyes

      Clinical Trials are Transforming Right Before Our Eyes

      Decentralized clinical trials, an innovation just a short time ago, are now mainstream.
      Kristin Brooks, Managing Editor, Contract Pharma 09.03.21

    • Clinical Trials | Information Technology | Promotions & Moves
      Clinical Ink Adds Executives

      Clinical Ink Adds Executives

      CCO Chris Crucitti, COO Brian Donahue, and VP Project Operations Bill Barrasso to manage eSource platforms.
      Kristin Brooks 05.04.21

    • Breaking News | Clinical Trials | Promotions & Moves
      Parexel Appoints Chief Patient Officer

      Parexel Appoints Chief Patient Officer

      Demonstrates the company’s commitment to elevating the patient perspective.
      Contract Pharma Staff 01.06.21


    • Clinical Trials | Drug Development | Information Technology
      Data Management in the Face of Growing Trial Complexity

      Data Management in the Face of Growing Trial Complexity

      Leveraging innovative processes and technology to help tackle the industry’s toughest data challenges
      Richard Young, Vice President, Veeva Vault EDC 04.22.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      AlzProtect & PAREXEL Biotech Enter Collaboration

      AlzProtect & PAREXEL Biotech Enter Collaboration

      For the performance of the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain
      03.25.19

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login